Company leader
Connie Lehman, MD, PhD
Founder and CEO
Clairity
Connie Lehman is the founder and chief executive of Clairity, the Boston company behind the first FDA-authorized AI that predicts a woman's five-year breast cancer risk from a mammogram. She is a professor of radiology at Harvard Medical School and one of the best-known researchers in breast imaging.
Training at Duke and Yale
Lehman graduated Phi Beta Kappa from Duke University and earned her MD and PhD at Yale University. She also holds an honorary medical degree from Harvard Medical School, according to her Clairity profile. She built her clinical career in breast imaging at Massachusetts General Hospital, where she was division chief of breast imaging, and she is now on leave from the hospital.
Predicting Risk With MIT
Her research spans computer-aided diagnosis, deep learning, breast density, predictive risk models, and imaging workflow, with more than 300 peer-reviewed publications. With MIT professor Regina Barzilay she built a deep learning model that predicts from a mammogram whether a woman is likely to develop breast cancer up to five years later. "Before we did not have accurate risk assessment tools that worked for individual women," she told MIT News in 2019. "Our work is the first to show that it's possible."
Founding Clairity
She founded Clairity in 2020 to bring image-based risk prediction into everyday screening. Clairity Breast won FDA De Novo authorization in June 2025, and in October 2026 it became available to women nationwide through Everlywell. "The information we need to understand a woman's breast cancer risk has been in her mammogram all along," she said at the Everlywell launch. Forbes included her among its 50 Over 50 innovators.